<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840097</url>
  </required_header>
  <id_info>
    <org_study_id>1023599</org_study_id>
    <nct_id>NCT02840097</nct_id>
  </id_info>
  <brief_title>Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study</brief_title>
  <acronym>TIC-TOC</acronym>
  <official_title>Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Nishijima, MD, MAS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Emergency Care Applied Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trauma is the leading cause of death and disability in children in the United States. The&#xD;
      long-term goal of this project is to evaluate the benefits and harms of tranexamic acid (TXA;&#xD;
      a drug that stops bleeding) in severely injured children. This is a 40-patient pilot study to&#xD;
      evaluate the feasibility of two subsequent large-scale studies of TXA in injured children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid (TXA), a drug that stops bleeding, is the only drug treatment that improves&#xD;
      survival in adults with serious bleeding after injuries. However, TXA has not been used&#xD;
      routinely in children with traumatic bleeding because no studies have appropriately evaluated&#xD;
      TXA for injured children. Such a study has the potential for significant impact in improving&#xD;
      the lives of injured children and their families, if found to be successful. The long-term&#xD;
      objective is to evaluate the benefits and risks of TXA in severely injured children. This&#xD;
      will be achieved by ultimately conducting two large-scale, multicenter, randomized controlled&#xD;
      trials of TXA use in severely injured children. One trial will evaluate TXA in children with&#xD;
      severe injuries to the body (&quot;torso injuries&quot;, i.e., to the abdomen and chest) and the second&#xD;
      trial will evaluate TXA in children with moderate-to-severe traumatic brain injuries (TBIs).&#xD;
      However, conducting a clinical trial in critically ill children is challenging due to lower&#xD;
      disease frequency and complex parent consent/child assent procedures. The investigators will&#xD;
      conduct a pilot study, designed similarly to the full-scale trials but with much smaller&#xD;
      patient enrollment, to assess the feasibility of, and fill crucial information gaps for the&#xD;
      two subsequent large-scale clinical trials. Injured children will be randomized to one of&#xD;
      three study arms: two different TXA doses or placebo. The specific aim of the proposed pilot&#xD;
      study is to demonstrate the ability to efficiently identify and enroll children with&#xD;
      hemorrhagic torso injuries or TBIs into a multicenter, randomized controlled pilot study&#xD;
      evaluating these two doses of TXA and placebo. The pilot study will enroll 40 children who&#xD;
      meet inclusion and exclusion criteria at 4 participating sites. To demonstrate the ability to&#xD;
      collect outcome measures, the investigators will collect the identical anticipated outcome&#xD;
      measures for the subsequent clinical trials: total blood products transfused over the initial&#xD;
      48 hours of care (torso injury trial), and intracranial hemorrhage progression in first 24&#xD;
      hours and neurocognitive function at 6 months after randomization (TBI trial). The&#xD;
      investigators will also collect safety outcomes, specifically venothromboembolic events&#xD;
      (i.e., blot clots in the blood vessels) and seizures within the initial 24 hours of study&#xD;
      drug. Additional objectives of this pilot study are to: evaluate the ability to efficiently&#xD;
      screen, identify, consent, randomize, and initiate the study intervention within 3 hours of&#xD;
      injury, assess protocol adherence and variability of care in enrolled patients, and identify&#xD;
      operational efficiencies with the potential to enhance the success of the subsequent trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">October 3, 2020</completion_date>
  <primary_completion_date type="Actual">October 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL)</measure>
    <time_frame>6 months</time_frame>
    <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL)</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale-Extended (GOS-E) Peds</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span Recall Test</measure>
    <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
    <description>Test of working memory; higher scores represent a better outcome, range from 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>First 48 hours after randomization</time_frame>
    <description>Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Hemorrhage Progression</measure>
    <time_frame>24 hours (±6 hours)</time_frame>
    <description>Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Non-cerebral Venous or Arterial Thrombosis</measure>
    <time_frame>Day 7 of hospitalization or hospital discharge (whichever comes first)</time_frame>
    <description>Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seizures</measure>
    <time_frame>24 hours after receiving drug</time_frame>
    <description>Clinical or electroencephalogram-documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Testing</measure>
    <time_frame>Baseline and completion of 8 hour infusion</time_frame>
    <description>Changes in coagulation biomarkers due to study intervention</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Wounds and Injuries</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
    <arm_group_label>Tranexamic acid dose A</arm_group_label>
    <arm_group_label>Tranexamic acid dose B</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline is provided to participants if randomized to this treatment arm.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Less than 18 years old AND&#xD;
&#xD;
          2. Penetrating torso trauma, blunt torso trauma, or head trauma as defined below.&#xD;
&#xD;
          3. Penetrating Torso Trauma:&#xD;
&#xD;
             a. Penetrating trauma to the chest, abdomen, neck, pelvis or thigh with at least one&#xD;
             of the following:&#xD;
&#xD;
               -  age-adjusted hypotension, or&#xD;
&#xD;
               -  age-adjusted tachycardia despite adequate resuscitation fluids, or&#xD;
&#xD;
               -  radiographic evidence of internal hemorrhage, or&#xD;
&#xD;
               -  clinician suspicion of ongoing internal hemorrhage&#xD;
&#xD;
          4. Blunt Torso Trauma (at least one of the following):&#xD;
&#xD;
               1. Clinician suspicion of hemorrhagic blunt torso injury and at least one of the&#xD;
                  following:&#xD;
&#xD;
                    -  age-adjusted hypotension, or&#xD;
&#xD;
                    -  persistent age-adjusted tachycardia despite adequate resuscitation fluids&#xD;
&#xD;
               2. Hemothorax on chest tube placement or imaging,&#xD;
&#xD;
               3. Clinical suspicion of hemorrhagic blunt torso injury and Intraperitoneal fluid on&#xD;
                  abdominal ultrasonography (Focused Assessment with Sonography in Trauma),&#xD;
&#xD;
               4. Intra-abdominal injury on CT with either contrast extravasation or more than&#xD;
                  trace intraperitoneal fluid,&#xD;
&#xD;
               5. Pelvic fracture with contrast extravasation or hematoma on abdominal/pelvic CT&#xD;
                  scan with at least one of the following:&#xD;
&#xD;
                    -  Age-adjusted tachycardia, or&#xD;
&#xD;
                    -  Age-adjusted hypotension.&#xD;
&#xD;
          5. Head Trauma:&#xD;
&#xD;
               1. Initial Glasgow Coma Scale (GCS) score 3 to 13 with associated intracranial&#xD;
                  hemorrhage on cranial CT scan (enroll after cranial CT scan)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to administer study drug within 3 hours of traumatic event&#xD;
&#xD;
          2. Known pregnancy&#xD;
&#xD;
          3. Known prisoners&#xD;
&#xD;
          4. Known wards of the state&#xD;
&#xD;
          5. Cardiac arrest prior to randomization&#xD;
&#xD;
          6. GCS score of 3 with bilateral unresponsive pupils&#xD;
&#xD;
          7. Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse axonal injury&#xD;
&#xD;
          8. Known bleeding/clotting disorders&#xD;
&#xD;
          9. Known seizure disorders&#xD;
&#xD;
         10. Known history of severe renal impairment&#xD;
&#xD;
         11. Unknown time of injury&#xD;
&#xD;
         12. Previous enrollment into the TIC-TOC trial&#xD;
&#xD;
         13. Prior TXA for current injury&#xD;
&#xD;
         14. Non-English and non-Spanish speaking&#xD;
&#xD;
         15. Known venous or arterial thrombosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel K Nishijima, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://tictoctrial.org/</url>
    <description>TIC-TOC trial website</description>
  </link>
  <results_reference>
    <citation>Nishijima DK, VanBuren J, Hewes HA, Myers SR, Stanley RM, Adelson PD, Barnhard SE, Bobinski M, Ghetti S, Holmes JF, Roberts I, Schalick WO 3rd, Tran NK, Tzimenatos LS, Michael Dean J, Kuppermann N; TIC-TOC Collaborators of the Pediatric Emergency Care Applied Research Network. Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. Trials. 2018 Oct 30;19(1):593. doi: 10.1186/s13063-018-2974-z.</citation>
    <PMID>30376893</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishijima DK, Gosdin M, Naz H, Tancredi DJ, Hewes HA, Myers SR, Stanley RM, Adelson PD, Burd RS, Finkelstein Y, VanBuren J, Casper TC, Kuppermann N; TIC-TOC Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN). Assessment of primary outcome measures for a clinical trial of pediatric hemorrhagic injuries. Am J Emerg Med. 2021 May;43:210-216. doi: 10.1016/j.ajem.2020.03.001. Epub 2020 Mar 9.</citation>
    <PMID>32278572</PMID>
  </results_reference>
  <results_reference>
    <citation>Trappey AF 3rd, Thompson KM, Kuppermann N, Stephenson JT, Nuno MA, Hewes HA, Meyers SR, Stanley RM, Galante JM, Nishijima DK; Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC) Collaborators of the Pediatric Emergency Care Applied Research Network (PECARN). Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process. J Trauma Acute Care Surg. 2019 Oct;87(4):935-943. doi: 10.1097/TA.0000000000002432.</citation>
    <PMID>31299040</PMID>
  </results_reference>
  <results_reference>
    <citation>Powers PE, Shore KK, Perez S, Ritley D, Kuppermann N, Holmes JF, Tzimenatos LS, Shawargga H, Nishijima DK. Public Deliberation as a Novel Method for an Exception From Informed Consent Community Consultation. Acad Emerg Med. 2019 Oct;26(10):1158-1168. doi: 10.1111/acem.13827. Epub 2019 Jul 24.</citation>
    <PMID>31271691</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <results_first_submitted>May 28, 2021</results_first_submitted>
  <results_first_submitted_qc>September 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Daniel Nishijima, MD, MAS</investigator_full_name>
    <investigator_title>Associate Professor, Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Brain injuries</keyword>
  <keyword>Wounds and injuries</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02840097/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid Dose A</title>
          <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="P2">
          <title>Tranexamic Acid Dose B</title>
          <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid Dose A</title>
          <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="B2">
          <title>Tranexamic Acid Dose B</title>
          <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="4.4"/>
                    <measurement group_id="B2" value="10.7" spread="4.0"/>
                    <measurement group_id="B3" value="9.2" spread="6.1"/>
                    <measurement group_id="B4" value="10.7" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>TBI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Torso</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Method of transport to the emergency department</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>EMS air</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>EMS ground</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Private vehicle/walk-in</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Interfacility transfer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple methods of transportation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from injury to emergency department arrival</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.5"/>
                    <measurement group_id="B2" value="1.2" spread="0.5"/>
                    <measurement group_id="B3" value="1.1" spread="0.8"/>
                    <measurement group_id="B4" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from injury to randomization</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="0.5"/>
                    <measurement group_id="B2" value="2.5" spread="0.4"/>
                    <measurement group_id="B3" value="2.4" spread="0.7"/>
                    <measurement group_id="B4" value="2.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary mechanism of injury</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fall from greater than standing height</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MVC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pedestrian/bicyclist hit by moving vehicle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Gun-shot wound</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Recreational vehicle injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sport-related injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Glasgow Coma Scale score (3 to 15)</title>
          <description>Scale is 3 to 15; lower scores represent more severe traumatic brain injury</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>TBI/Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" lower_limit="10" upper_limit="13"/>
                    <measurement group_id="B2" value="11" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="B3" value="3" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="B4" value="9" lower_limit="3" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Torso</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="B2" value="15" lower_limit="14" upper_limit="15"/>
                    <measurement group_id="B3" value="15" lower_limit="9" upper_limit="15"/>
                    <measurement group_id="B4" value="15" lower_limit="9" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Emergency department disposition</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Operating room</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Admit</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient received craniotomy or craniectomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient received an intracranial pressure monitor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient received a laparotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient received a thoracotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of hospitalization</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="8.0"/>
                    <measurement group_id="B2" value="13.6" spread="14.7"/>
                    <measurement group_id="B3" value="22.3" spread="28.2"/>
                    <measurement group_id="B4" value="15.4" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury Severity Scale score (0 to 75)</title>
          <description>Scale is 0 to 75 with higher scores representing more severe injury</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.1" spread="5.8"/>
                    <measurement group_id="B2" value="15.2" spread="5.7"/>
                    <measurement group_id="B3" value="13.8" spread="5.7"/>
                    <measurement group_id="B4" value="14.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of peritoneal free fluid on initial focused assessment with sonography for trauma exam</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pH</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="0.1"/>
                    <measurement group_id="B2" value="7.3" spread="0.1"/>
                    <measurement group_id="B3" value="7.3" spread="0.1"/>
                    <measurement group_id="B4" value="7.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum bicarbonate</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.4" spread="2.2"/>
                    <measurement group_id="B2" value="22.0" spread="1.7"/>
                    <measurement group_id="B3" value="21.5" spread="3.2"/>
                    <measurement group_id="B4" value="21.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.2"/>
                    <measurement group_id="B2" value="0.6" spread="0.2"/>
                    <measurement group_id="B3" value="0.6" spread="0.3"/>
                    <measurement group_id="B4" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Normalized Ratio</title>
          <description>Normal range is 0.8 to 1.1</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.1"/>
                    <measurement group_id="B2" value="1.1" spread="0.2"/>
                    <measurement group_id="B3" value="1.2" spread="0.2"/>
                    <measurement group_id="B4" value="1.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" spread="1.1"/>
                    <measurement group_id="B2" value="13.1" spread="1.9"/>
                    <measurement group_id="B3" value="12.5" spread="2.0"/>
                    <measurement group_id="B4" value="12.8" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets</title>
          <units>platelets per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="323.5" spread="117.9"/>
                    <measurement group_id="B2" value="285.0" spread="136.5"/>
                    <measurement group_id="B3" value="374.7" spread="138.7"/>
                    <measurement group_id="B4" value="329.7" spread="133.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular filtration rate ()</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Moderate renal dysfunction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal renal function</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pediatric Quality of Life Inventory (PedsQL)</title>
        <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Inventory (PedsQL)</title>
          <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units.</description>
          <units>Quality of life units * months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="19.0"/>
                    <measurement group_id="O2" value="60.2" spread="12.3"/>
                    <measurement group_id="O3" value="67.2" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pediatric Quality of Life Inventory (PedsQL)</title>
        <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes</description>
        <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Inventory (PedsQL)</title>
          <description>Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="24.0"/>
                    <measurement group_id="O2" value="52.4" spread="20.1"/>
                    <measurement group_id="O3" value="57.9" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="19.8"/>
                    <measurement group_id="O2" value="61.5" spread="16.9"/>
                    <measurement group_id="O3" value="60.5" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" spread="23.6"/>
                    <measurement group_id="O2" value="77.5" spread="18.5"/>
                    <measurement group_id="O3" value="68.9" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="23.0"/>
                    <measurement group_id="O2" value="84.3" spread="9.9"/>
                    <measurement group_id="O3" value="68.9" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glasgow Outcome Scale-Extended (GOS-E) Peds</title>
        <description>Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery</description>
        <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Glasgow Outcome Scale-Extended (GOS-E) Peds</title>
          <description>Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.3"/>
                    <measurement group_id="O2" value="5.2" spread="1.8"/>
                    <measurement group_id="O3" value="5.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.0"/>
                    <measurement group_id="O2" value="5.1" spread="1.4"/>
                    <measurement group_id="O3" value="4.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.3"/>
                    <measurement group_id="O2" value="4.6" spread="1.3"/>
                    <measurement group_id="O3" value="4.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.6"/>
                    <measurement group_id="O2" value="2.9" spread="2.3"/>
                    <measurement group_id="O3" value="4.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Digit Span Recall Test</title>
        <description>Test of working memory; higher scores represent a better outcome, range from 0 to infinity</description>
        <time_frame>1 week, 1 month, 3 months, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Span Recall Test</title>
          <description>Test of working memory; higher scores represent a better outcome, range from 0 to infinity</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total forward digit span, 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.7"/>
                    <measurement group_id="O2" value="8.4" spread="4.3"/>
                    <measurement group_id="O3" value="8.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total backward digit span, 1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.6"/>
                    <measurement group_id="O2" value="6.0" spread="3.3"/>
                    <measurement group_id="O3" value="7.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total forward digit span, 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.9"/>
                    <measurement group_id="O2" value="7.9" spread="3.7"/>
                    <measurement group_id="O3" value="7.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total backward digit span, 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.8"/>
                    <measurement group_id="O2" value="6.2" spread="1.3"/>
                    <measurement group_id="O3" value="5.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total forward digit span, 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="3.6"/>
                    <measurement group_id="O2" value="10.4" spread="1.5"/>
                    <measurement group_id="O3" value="8.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total backward digit span, 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="3.6"/>
                    <measurement group_id="O2" value="7.8" spread="0.8"/>
                    <measurement group_id="O3" value="6.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total forward digit span, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="3.9"/>
                    <measurement group_id="O2" value="10.0" spread="2.4"/>
                    <measurement group_id="O3" value="8.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total backward digit span, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="4.1"/>
                    <measurement group_id="O2" value="6.0" spread="2.4"/>
                    <measurement group_id="O3" value="5.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfusion</title>
        <description>Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate</description>
        <time_frame>First 48 hours after randomization</time_frame>
        <population>Torso and Both groups</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate</description>
          <population>Torso and Both groups</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.4" spread="821.5"/>
                    <measurement group_id="O2" value="150.4" spread="214.1"/>
                    <measurement group_id="O3" value="303.6" spread="571.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracranial Hemorrhage Progression</title>
        <description>Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT.</description>
        <time_frame>24 hours (±6 hours)</time_frame>
        <population>Brain Injury and Both groups</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Intracranial Hemorrhage Progression</title>
          <description>Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT.</description>
          <population>Brain Injury and Both groups</population>
          <units>Proportional change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.004"/>
                    <measurement group_id="O2" value="0.001" spread="0.001"/>
                    <measurement group_id="O3" value="0.003" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Non-cerebral Venous or Arterial Thrombosis</title>
        <description>Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization</description>
        <time_frame>Day 7 of hospitalization or hospital discharge (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-cerebral Venous or Arterial Thrombosis</title>
          <description>Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seizures</title>
        <description>Clinical or electroencephalogram-documented</description>
        <time_frame>24 hours after receiving drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seizures</title>
          <description>Clinical or electroencephalogram-documented</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Testing</title>
        <description>Changes in coagulation biomarkers due to study intervention</description>
        <time_frame>Baseline and completion of 8 hour infusion</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid Dose A</title>
            <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid Dose B</title>
            <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Testing</title>
          <description>Changes in coagulation biomarkers due to study intervention</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse Events were monitored/assessed without regard to the specific Adverse Event; defined as any untoward medical occurrence experienced by a subject; may constitute a disease, a set of related signs or symptoms, or a single sign or symptom</desc>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid Dose A</title>
          <description>Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="E2">
          <title>Tranexamic Acid Dose B</title>
          <description>Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.&#xD;
Tranexamic Acid: Active drug is provided to participants as described based on the TXA arm they are randomized to.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.&#xD;
Placebo: Normal saline is provided to participants if randomized to this treatment arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Event</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Nishijima, Study Co-PI</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916.734.3884</phone>
      <email>dnishijima@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

